 Timothy Garrington
Concepts (292)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rhabdomyosarcoma | 1 | 2019 | 54 | 0.610 |
Why?
| | Central Nervous System Neoplasms | 1 | 2019 | 126 | 0.570 |
Why?
| | MAP Kinase Kinase Kinases | 6 | 2004 | 68 | 0.550 |
Why?
| | Mitogen-Activated Protein Kinases | 7 | 2004 | 278 | 0.430 |
Why?
| | Hodgkin Disease | 2 | 2016 | 120 | 0.410 |
Why?
| | Kidney Neoplasms | 3 | 2021 | 327 | 0.360 |
Why?
| | Neuroblastoma | 3 | 2017 | 133 | 0.360 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 4 | 2004 | 113 | 0.330 |
Why?
| | Adrenal Gland Neoplasms | 2 | 2014 | 81 | 0.320 |
Why?
| | Beckwith-Wiedemann Syndrome | 1 | 2008 | 6 | 0.320 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2009 | 113 | 0.320 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2008 | 52 | 0.300 |
Why?
| | Asparaginase | 2 | 1998 | 31 | 0.300 |
Why?
| | Positron-Emission Tomography | 1 | 2009 | 259 | 0.300 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2008 | 48 | 0.300 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 4 | 2004 | 144 | 0.290 |
Why?
| | Histiocytosis, Langerhans-Cell | 2 | 2020 | 35 | 0.290 |
Why?
| | Pancreatitis | 2 | 1998 | 107 | 0.280 |
Why?
| | Mast Cells | 3 | 2003 | 116 | 0.270 |
Why?
| | Child, Preschool | 17 | 2021 | 9106 | 0.270 |
Why?
| | Neoplasms | 5 | 2022 | 2097 | 0.270 |
Why?
| | MAP Kinase Kinase Kinase 2 | 7 | 2012 | 12 | 0.260 |
Why?
| | Adaptor Proteins, Signal Transducing | 4 | 2003 | 367 | 0.250 |
Why?
| | Testicular Neoplasms | 2 | 2017 | 96 | 0.250 |
Why?
| | MAP Kinase Kinase Kinase 1 | 2 | 2005 | 14 | 0.240 |
Why?
| | Child | 20 | 2022 | 18402 | 0.230 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2004 | 83 | 0.220 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 2 | 2016 | 62 | 0.220 |
Why?
| | Lung Neoplasms | 2 | 2021 | 2177 | 0.220 |
Why?
| | MAP Kinase Signaling System | 3 | 2008 | 276 | 0.220 |
Why?
| | Parental Leave | 1 | 2022 | 17 | 0.210 |
Why?
| | Adolescent | 17 | 2021 | 17830 | 0.200 |
Why?
| | Anemia | 1 | 2023 | 143 | 0.200 |
Why?
| | Tomography, X-Ray Computed | 2 | 2021 | 2279 | 0.200 |
Why?
| | Sarcoma | 2 | 2015 | 137 | 0.200 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 172 | 0.190 |
Why?
| | Thrombocytopenia | 1 | 2023 | 177 | 0.190 |
Why?
| | Pulmonary Blastoma | 1 | 2021 | 8 | 0.190 |
Why?
| | Fibroblasts | 3 | 2005 | 837 | 0.190 |
Why?
| | Circulating Tumor DNA | 1 | 2021 | 22 | 0.180 |
Why?
| | RNA, Neoplasm | 1 | 2021 | 80 | 0.180 |
Why?
| | Stem Cell Factor | 1 | 2000 | 14 | 0.180 |
Why?
| | Ribonuclease III | 1 | 2021 | 34 | 0.180 |
Why?
| | Pituitary Diseases | 1 | 2020 | 22 | 0.180 |
Why?
| | Receptors, IgE | 1 | 2000 | 40 | 0.180 |
Why?
| | Sertoli-Leydig Cell Tumor | 1 | 2020 | 8 | 0.180 |
Why?
| | Rhabdomyosarcoma, Embryonal | 1 | 2020 | 16 | 0.180 |
Why?
| | DEAD-box RNA Helicases | 1 | 2021 | 56 | 0.180 |
Why?
| | Cholestasis | 1 | 2023 | 225 | 0.180 |
Why?
| | Sarcoma, Ewing | 1 | 2021 | 64 | 0.180 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2020 | 28 | 0.170 |
Why?
| | Pituitary Gland | 1 | 2020 | 148 | 0.170 |
Why?
| | Survival Rate | 3 | 2019 | 1644 | 0.170 |
Why?
| | Fellowships and Scholarships | 1 | 2022 | 227 | 0.170 |
Why?
| | Infant | 11 | 2020 | 7954 | 0.170 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2020 | 192 | 0.160 |
Why?
| | Polycystic Kidney Diseases | 1 | 2019 | 55 | 0.160 |
Why?
| | Disease-Free Survival | 2 | 2019 | 620 | 0.160 |
Why?
| | Antibodies, Neutralizing | 1 | 2020 | 221 | 0.150 |
Why?
| | Female | 21 | 2021 | 59461 | 0.150 |
Why?
| | Cancer Survivors | 1 | 2022 | 205 | 0.150 |
Why?
| | Humans | 33 | 2023 | 114616 | 0.150 |
Why?
| | Octreotide | 1 | 1998 | 26 | 0.150 |
Why?
| | Biopsy, Large-Core Needle | 1 | 2017 | 11 | 0.150 |
Why?
| | Abdominal Neoplasms | 1 | 2017 | 26 | 0.150 |
Why?
| | Frozen Sections | 1 | 2017 | 24 | 0.140 |
Why?
| | Wilms Tumor | 1 | 2018 | 68 | 0.140 |
Why?
| | Cytodiagnosis | 1 | 2017 | 29 | 0.140 |
Why?
| | Cytokines | 2 | 2004 | 1840 | 0.140 |
Why?
| | Seminoma | 1 | 2017 | 17 | 0.140 |
Why?
| | Male | 20 | 2021 | 55549 | 0.140 |
Why?
| | Interferon-gamma | 1 | 2020 | 719 | 0.140 |
Why?
| | Protein Processing, Post-Translational | 1 | 1999 | 399 | 0.140 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2003 | 1139 | 0.130 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 1999 | 333 | 0.130 |
Why?
| | Ovarian Neoplasms | 1 | 2020 | 388 | 0.130 |
Why?
| | Health Planning | 1 | 2015 | 46 | 0.120 |
Why?
| | Enzyme Activation | 5 | 2004 | 785 | 0.120 |
Why?
| | Genetic Predisposition to Disease | 2 | 2021 | 2084 | 0.120 |
Why?
| | Transition to Adult Care | 1 | 2015 | 62 | 0.120 |
Why?
| | Mediastinal Neoplasms | 1 | 2014 | 33 | 0.120 |
Why?
| | Transcription Factor AP-1 | 2 | 2005 | 80 | 0.120 |
Why?
| | Thoracoscopy | 1 | 2014 | 57 | 0.110 |
Why?
| | Disease Management | 2 | 2015 | 560 | 0.110 |
Why?
| | Carrier Proteins | 4 | 2003 | 695 | 0.110 |
Why?
| | Xanthogranuloma, Juvenile | 1 | 2013 | 4 | 0.110 |
Why?
| | Biopsy | 1 | 2017 | 1036 | 0.110 |
Why?
| | Arabinonucleosides | 1 | 2013 | 8 | 0.110 |
Why?
| | Adenine Nucleotides | 1 | 2013 | 18 | 0.110 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1262 | 0.110 |
Why?
| | Histiocytosis, Sinus | 1 | 2013 | 7 | 0.110 |
Why?
| | Ambulatory Care Facilities | 1 | 2015 | 213 | 0.110 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2013 | 81 | 0.110 |
Why?
| | Anesthesia | 1 | 2014 | 117 | 0.100 |
Why?
| | Prevalence | 1 | 2019 | 2249 | 0.100 |
Why?
| | Salvage Therapy | 1 | 2013 | 127 | 0.100 |
Why?
| | Heart Diseases | 1 | 2016 | 330 | 0.100 |
Why?
| | Diagnostic Imaging | 1 | 2014 | 275 | 0.100 |
Why?
| | Retrospective Studies | 6 | 2020 | 12542 | 0.100 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2012 | 141 | 0.100 |
Why?
| | Gene Expression Regulation | 4 | 2012 | 2319 | 0.100 |
Why?
| | Signal Transduction | 3 | 2004 | 4509 | 0.100 |
Why?
| | Ventricular Remodeling | 1 | 2012 | 226 | 0.090 |
Why?
| | Program Development | 2 | 2015 | 341 | 0.090 |
Why?
| | Stem Cells | 2 | 2008 | 545 | 0.090 |
Why?
| | Pediatrics | 2 | 2008 | 979 | 0.090 |
Why?
| | Laparoscopy | 1 | 2014 | 398 | 0.090 |
Why?
| | Primary Health Care | 2 | 2022 | 1512 | 0.090 |
Why?
| | Subtraction Technique | 1 | 2009 | 24 | 0.080 |
Why?
| | Radiopharmaceuticals | 1 | 2009 | 157 | 0.080 |
Why?
| | Myocytes, Cardiac | 1 | 2012 | 449 | 0.080 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2008 | 48 | 0.080 |
Why?
| | Polymerase Chain Reaction | 2 | 2021 | 993 | 0.080 |
Why?
| | Liver Neoplasms | 1 | 2012 | 506 | 0.080 |
Why?
| | Infant, Newborn | 4 | 2023 | 5040 | 0.070 |
Why?
| | Antineoplastic Agents | 1 | 1998 | 1879 | 0.070 |
Why?
| | Heart Ventricles | 1 | 2012 | 709 | 0.070 |
Why?
| | Adult | 6 | 2019 | 30528 | 0.070 |
Why?
| | Prognosis | 4 | 2020 | 3328 | 0.070 |
Why?
| | Young Adult | 6 | 2018 | 10455 | 0.070 |
Why?
| | Embryo, Mammalian | 2 | 2005 | 213 | 0.070 |
Why?
| | Hypoxia | 1 | 2012 | 956 | 0.070 |
Why?
| | Risk Assessment | 1 | 2015 | 2967 | 0.070 |
Why?
| | Mitogen-Activated Protein Kinase 7 | 4 | 2012 | 15 | 0.070 |
Why?
| | Age Factors | 3 | 2018 | 2894 | 0.060 |
Why?
| | Leukemia | 1 | 2008 | 209 | 0.060 |
Why?
| | Acute Disease | 2 | 1998 | 910 | 0.060 |
Why?
| | Cell Line | 5 | 2003 | 2635 | 0.060 |
Why?
| | Epidermal Growth Factor | 2 | 2003 | 161 | 0.060 |
Why?
| | Education, Medical, Undergraduate | 1 | 2007 | 159 | 0.060 |
Why?
| | Transcription Factors | 2 | 2021 | 1527 | 0.060 |
Why?
| | Killer Cells, Natural | 1 | 2008 | 380 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2005 | 47 | 0.060 |
Why?
| | SEER Program | 2 | 2016 | 196 | 0.060 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2005 | 91 | 0.060 |
Why?
| | Phosphorylation | 3 | 2012 | 1569 | 0.060 |
Why?
| | DNA Methylation | 1 | 2008 | 495 | 0.060 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2004 | 23 | 0.060 |
Why?
| | Neoplasm Metastasis | 2 | 2018 | 522 | 0.060 |
Why?
| | Blotting, Western | 2 | 2004 | 1147 | 0.060 |
Why?
| | Genes, jun | 1 | 2003 | 9 | 0.060 |
Why?
| | Survival Analysis | 2 | 2018 | 1211 | 0.060 |
Why?
| | Mice | 6 | 2012 | 14859 | 0.060 |
Why?
| | Myogenic Regulatory Factors | 1 | 2003 | 49 | 0.060 |
Why?
| | Animals | 9 | 2012 | 31692 | 0.060 |
Why?
| | Tissue Donors | 1 | 2005 | 316 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2012 | 2565 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 1 | 2004 | 397 | 0.050 |
Why?
| | Promoter Regions, Genetic | 3 | 2005 | 1131 | 0.050 |
Why?
| | Macromolecular Substances | 2 | 2003 | 200 | 0.050 |
Why?
| | Cell Differentiation | 2 | 2000 | 1699 | 0.050 |
Why?
| | Databases, Factual | 2 | 2018 | 1124 | 0.050 |
Why?
| | Recurrence | 3 | 2013 | 935 | 0.050 |
Why?
| | Survivors | 2 | 2016 | 411 | 0.050 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2005 | 256 | 0.050 |
Why?
| | src-Family Kinases | 1 | 2003 | 88 | 0.050 |
Why?
| | Mutation | 3 | 2020 | 3344 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 797 | 0.050 |
Why?
| | Cells, Cultured | 3 | 2005 | 3881 | 0.050 |
Why?
| | Hypertension, Pulmonary | 1 | 2012 | 1727 | 0.050 |
Why?
| | Survivorship | 1 | 2022 | 39 | 0.050 |
Why?
| | Curriculum | 1 | 2007 | 819 | 0.050 |
Why?
| | Transcription, Genetic | 2 | 2005 | 1313 | 0.050 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2008 | 395 | 0.050 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 1 | 2021 | 17 | 0.050 |
Why?
| | RNA-Binding Protein EWS | 1 | 2021 | 17 | 0.050 |
Why?
| | Kidney Diseases, Cystic | 1 | 2021 | 21 | 0.050 |
Why?
| | Receptor Aggregation | 1 | 2000 | 8 | 0.050 |
Why?
| | Translocation, Genetic | 1 | 2021 | 94 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 4620 | 0.050 |
Why?
| | Pneumothorax | 1 | 2021 | 42 | 0.040 |
Why?
| | Reoviridae | 1 | 2000 | 35 | 0.040 |
Why?
| | Chemokine CXCL9 | 1 | 2020 | 21 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2021 | 130 | 0.040 |
Why?
| | Syndrome | 1 | 2021 | 333 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2000 | 140 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2020 | 4411 | 0.040 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2000 | 345 | 0.040 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2000 | 260 | 0.040 |
Why?
| | Mating Factor | 1 | 1999 | 3 | 0.040 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2021 | 179 | 0.040 |
Why?
| | Cell Compartmentation | 1 | 1999 | 51 | 0.040 |
Why?
| | Receptors, Growth Factor | 1 | 1999 | 49 | 0.040 |
Why?
| | TRPP Cation Channels | 1 | 2019 | 63 | 0.040 |
Why?
| | Growth Substances | 1 | 1999 | 138 | 0.040 |
Why?
| | Insect Proteins | 1 | 1999 | 31 | 0.040 |
Why?
| | Education, Medical, Graduate | 1 | 2022 | 368 | 0.040 |
Why?
| | Transcriptional Activation | 1 | 2000 | 337 | 0.040 |
Why?
| | Age of Onset | 1 | 2020 | 445 | 0.040 |
Why?
| | Fungal Proteins | 1 | 1999 | 119 | 0.040 |
Why?
| | United States | 3 | 2022 | 12176 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2000 | 430 | 0.040 |
Why?
| | Chronic Disease | 2 | 2015 | 1578 | 0.040 |
Why?
| | Dexamethasone | 1 | 2020 | 317 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2005 | 1313 | 0.040 |
Why?
| | MAP Kinase Kinase 5 | 3 | 2003 | 4 | 0.040 |
Why?
| | Cytoskeleton | 1 | 1999 | 176 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 811 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1121 | 0.040 |
Why?
| | Hepatoblastoma | 1 | 2017 | 27 | 0.040 |
Why?
| | Drosophila melanogaster | 1 | 1999 | 191 | 0.040 |
Why?
| | Receptors, Cell Surface | 1 | 2019 | 355 | 0.040 |
Why?
| | Mammals | 1 | 1999 | 244 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 951 | 0.040 |
Why?
| | Intraoperative Period | 1 | 2017 | 51 | 0.030 |
Why?
| | Microtubules | 1 | 1999 | 237 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 447 | 0.030 |
Why?
| | Teratoma | 1 | 2017 | 92 | 0.030 |
Why?
| | Stress, Physiological | 1 | 1999 | 378 | 0.030 |
Why?
| | Caenorhabditis elegans | 1 | 1999 | 268 | 0.030 |
Why?
| | Epidemiological Monitoring | 1 | 2016 | 47 | 0.030 |
Why?
| | Saccharomyces cerevisiae | 1 | 1999 | 476 | 0.030 |
Why?
| | Time Factors | 2 | 2018 | 6112 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2021 | 1040 | 0.030 |
Why?
| | Parents | 1 | 2022 | 1186 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 520 | 0.030 |
Why?
| | Neurilemmoma | 1 | 2014 | 19 | 0.030 |
Why?
| | Organizational Innovation | 1 | 2015 | 132 | 0.030 |
Why?
| | Apoptosis | 2 | 2000 | 2362 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2015 | 183 | 0.030 |
Why?
| | Peptides | 1 | 1999 | 848 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 2762 | 0.030 |
Why?
| | Lymphoma | 1 | 2014 | 177 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2017 | 1167 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2000 | 2552 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2000 | 1736 | 0.030 |
Why?
| | Logistic Models | 1 | 2018 | 1840 | 0.030 |
Why?
| | MAP Kinase Kinase 7 | 2 | 2003 | 6 | 0.030 |
Why?
| | Colorado | 2 | 2015 | 4099 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2015 | 1226 | 0.030 |
Why?
| | Two-Hybrid System Techniques | 2 | 2003 | 52 | 0.020 |
Why?
| | Aged | 2 | 2022 | 19061 | 0.020 |
Why?
| | Program Evaluation | 1 | 2015 | 822 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2020 | 9084 | 0.020 |
Why?
| | Transfection | 2 | 2003 | 866 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2012 | 477 | 0.020 |
Why?
| | Ultrasonography | 1 | 2012 | 633 | 0.020 |
Why?
| | Receptor, IGF Type 1 | 1 | 2008 | 58 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1177 | 0.020 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2008 | 98 | 0.020 |
Why?
| | Drug Design | 1 | 2008 | 148 | 0.020 |
Why?
| | Pancreatic Neoplasms | 1 | 2014 | 731 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2008 | 239 | 0.020 |
Why?
| | Clinical Clerkship | 1 | 2007 | 72 | 0.020 |
Why?
| | Medical Oncology | 1 | 2008 | 229 | 0.020 |
Why?
| | Schools, Medical | 1 | 2007 | 120 | 0.020 |
Why?
| | Middle Aged | 2 | 2017 | 26719 | 0.020 |
Why?
| | Protein Binding | 2 | 2003 | 1888 | 0.020 |
Why?
| | Prospective Studies | 1 | 2017 | 6214 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2008 | 498 | 0.020 |
Why?
| | Histocompatibility Testing | 1 | 2005 | 116 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2016 | 6344 | 0.020 |
Why?
| | Fos-Related Antigen-2 | 1 | 2005 | 1 | 0.020 |
Why?
| | Oligonucleotide Probes | 1 | 2005 | 54 | 0.020 |
Why?
| | Faculty, Medical | 1 | 2007 | 228 | 0.020 |
Why?
| | Urokinase-Type Plasminogen Activator | 1 | 2005 | 28 | 0.020 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 2005 | 153 | 0.020 |
Why?
| | Dimerization | 1 | 2005 | 176 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2008 | 1083 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 2005 | 377 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 2008 | 931 | 0.010 |
Why?
| | MEF2 Transcription Factors | 1 | 2003 | 55 | 0.010 |
Why?
| | Graft vs Host Disease | 1 | 2005 | 212 | 0.010 |
Why?
| | Mink | 1 | 2003 | 12 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2012 | 3531 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 2003 | 173 | 0.010 |
Why?
| | Amino Acid Motifs | 1 | 2003 | 197 | 0.010 |
Why?
| | Cell Nucleus | 1 | 2005 | 554 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2005 | 1430 | 0.010 |
Why?
| | Models, Biological | 1 | 2008 | 1620 | 0.010 |
Why?
| | Base Sequence | 1 | 2005 | 2114 | 0.010 |
Why?
| | MAP Kinase Kinase Kinase 3 | 1 | 2000 | 3 | 0.010 |
Why?
| | Fas-Associated Death Domain Protein | 1 | 2000 | 8 | 0.010 |
Why?
| | Caspase 8 | 1 | 2000 | 43 | 0.010 |
Why?
| | Caspase 9 | 1 | 2000 | 48 | 0.010 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2000 | 40 | 0.010 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2000 | 26 | 0.010 |
Why?
| | COS Cells | 1 | 2000 | 175 | 0.010 |
Why?
| | Antigen-Presenting Cells | 1 | 2000 | 150 | 0.010 |
Why?
| | fas Receptor | 1 | 2000 | 91 | 0.010 |
Why?
| | Caspase Inhibitors | 1 | 2000 | 78 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 1355 | 0.010 |
Why?
| | Oxidants | 1 | 2000 | 112 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2005 | 2785 | 0.010 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2000 | 171 | 0.010 |
Why?
| | Caspases | 1 | 2000 | 245 | 0.010 |
Why?
| | Hydrogen Peroxide | 1 | 2000 | 288 | 0.010 |
Why?
| | Mitosis | 1 | 1999 | 164 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2003 | 950 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2003 | 1076 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 2000 | 1037 | 0.010 |
Why?
| | Kidney | 1 | 2003 | 1187 | 0.010 |
Why?
|
|
Garrington's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|